Ahmad Ainurofiq

Dr. Ahmad Ainurofiq

Department of Pharmacy, Sebelas Maret University
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Reports in Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
Ahmad AinurofiqAhmad Ainurofiq
Ahmad Ainurofiq
DPDavid Sarono Putro
David Sarono Putro
DRDhea Aqila Ramadhani
Dhea Aqila Ramadhani
GPGemala Mahendra Putra
Gemala Mahendra Putra
LSLaura Da Costa Do Espirito Santo
Laura Da Costa Do Espirito Santo
One of the most important parameters in pharmacy is drug solubility. Solubility affects the efficacy of a drug. Drug solubility has an important role in determining the concentration of a drug to achieve the necessary pharmacological response, as all drugs absorbed by the body must be in the form of a solution. Drug solubility is quite a common issue and affects the bioavailability of a drug in the body. Drugs with low solubility are poorly absorbed, resulting in poor bioavailability. Many methods have been developed for increasing the solubility of a drug. In this review, we will describe possible efforts for improving the solubility of a drug, e.g., reducing particle size, surfactants, the use of nanosuspension technology, solid dispersion, salt formation, pH adjustment, hydrotropy, cocrystal, amorphous compound formation, and inclusion complexes. The main objective of this review was to focus on efforts that can increase the solubility of a drug to obtain good drug efficacy.

1 January 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Ahmad AinurofiqAhmad Ainurofiq
Ahmad Ainurofiq
RMRachmat Mauludin
Rachmat Mauludin
DMDiky Mudhakir
Diky Mudhakir
DUDaiki Umeda
Daiki Umeda
SSSundani Nurono Soewandhi
Sundani Nurono Soewandhi
Etsuo YonemochiEtsuo Yonemochi
Etsuo Yonemochi

6 July 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ahmad AinurofiqAhmad Ainurofiq
Ahmad Ainurofiq
RMRachmat Mauludin
Rachmat Mauludin
DMDiky Mudhakir
Diky Mudhakir
SSSundani Nurono Soewandhi
Sundani Nurono Soewandhi
Low physical stability is the limitation of the widespread use of amorphous drugs. The co-amorphous drug system is a new and emerging method for preparing a stable amorphous form. Co-amorphous is a single-phase amorphous multicomponent system consisting of two or more small molecules that are a combination of drugs or drugs and excipients. The co-amorphous system that uses benzoic acid (BA) as an excipient was studied to improve the physical stability, dissolution, and solubility of desloratadine (DES). In this study, the co-amorphous formation of DES and BA (DES–BA) was prepared by melt-quenching method and characterized by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction (PXRD), and polarized light microscopy (PLM). Dissolution, solubility, and physical stability profiles of DES–BA were determined. The DES crystals were converted into DES–BA co-amorphous form to reveal the molecular interactions between DES and BA. Solid-state analysis proved that the co-amorphous DES–BA system (1:1) is amorphous and homogeneous. The DSC experiment showed that the glass transition temperature (Tg) of tested DES–BA co-amorphous had a higher single Tg compared to the amorphous DES. FTIR revealed strong interactions, especially salt formation. The dissolution rate and solubility of co-amorphous DES–BA (1:1) obtained were larger than the DES in crystalline form. The PXRD technique was used to assess physical stability for three months at 40 °C with 75% RH. The DES–BA co-amorphous system demonstrated better physical stability than a single form of amorphous DES. Co-amorphous DES–BA has demonstrated the potential for improving solid-state stability, as the formation of DES–BA co-amorphous salt increased solubility and dissolution when compared to pure crystalline DES. This study also demonstrated the possibility for developing a DES–BA co-amorphous system toward oral formulations to improve DES solubility and bioavailability.

8 December 2016 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
Ahmad AinurofiqAhmad Ainurofiq
Ahmad Ainurofiq
SCSyaiful Choiri
Syaiful Choiri
The purpose of this research was to develop an inclusion complex of meloxicam (MEL)/β-cyclodextrin (β-CD) incorporated into an orally disintegrating tablet (ODT), using statistical analysis to optimize the ODT formulation based on a quality by design (QbD) approach. MEL/β-CD complexation was performed by kneading, co-precipitation and spray drying methods under different molar ratios. Fourier transform infrared spectroscopy, X-ray diffraction and thermal analysis were utilized to evaluate the complexes. A central composite design (α = 2) was applied to optimize and assess the influence of Primojel, Primellose and crushing strength (CS) as independent variables on tablet friability, disintegration behavior, wicking properties and drug release. The spray drying method induced formation of an amorphous complex and enhanced solubility and drug release of MEL. Furthermore, a QbD-based statistical analysis was successfully utilized to optimize the ODT formulation. Primojel, Primellose and CS showed unique main effects and interactions at different levels. CS was the dominant factor, affecting friability, disintegration behavior and drug release, while wicking properties were affected by Primojel and its interaction with Primellose. Therefore, according to the overlay plot, CS was dominant factor in determining the optimum region based on a QbD approach.

10 July 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Ahmad AinurofiqAhmad Ainurofiq
Ahmad Ainurofiq
BRBingah Ginanjar Rahayu
Bingah Ginanjar Rahayu
FMFaradisania Adnan Murtadla
Faradisania Adnan Murtadla
IKIlham Kuncahyo
Ilham Kuncahyo
AWAnjar Windarsih
Anjar Windarsih
SCSyaiful Choiri
Syaiful Choiri

5 April 2020 in International Journal of Research in Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
Ahmad AinurofiqAhmad Ainurofiq
Ahmad Ainurofiq
KDKezia Esther Dinda
Kezia Esther Dinda
MPMaya Widia Pangestika
Maya Widia Pangestika
UHUlia Himawati
Ulia Himawati
WWWening Dyah Wardhani
Wening Dyah Wardhani
YSYustika Tamarin Sipahutar
Yustika Tamarin Sipahutar
Active pharmaceutical ingredients (API) are the main components in the production process of pharmaceutical products. If the API has a good quality, then it will lead to good pharmaceutical products. API consists of more than one different crystal form which, then forms a polymorph through the process of polymorphism. Until now, API polymorphism is still a big challenge in the pharmaceutical industry. That is because the nature of polymorphism is difficult to predict. One of them is by crystallizing molecules in one or many crystalline forms or combining with other molecules to form stable co-crystal. This process will lead to several polymorph forms of one certain API. Sometimes, these forms will have characteristics that differ one to another. Each polymorph has different mechanical, physical, thermal, and chemical properties that will affect the solubility, dissolution, bioavailability, stability, bioequivalence, and manufacturing of the API. Therefore to know the nature of an API, it is necessary to characterize the polymorphic form of the API before. If the form is not incompatible with the formulation, it can cause a failure in the production process. This review will discuss the effect of polymorphism on the physicochemical properties of API. It is hoped that this review can become the basis for improving the stability and effectiveness of pharmaceutical products.